Cytogenetic and molecular genetic aspects of idiopathic myelofibrosis

被引:20
作者
Reilly, JT [1 ]
机构
[1] Royal Hallamshire Hosp, Div Genom Med, Acad Unit Haematol, Sheffield S10 2JF, S Yorkshire, England
关键词
cytogenetics; idiopathic myelofibrosis; prognosis; 13q; 20q; trisomy; 1q;
D O I
10.1159/000064708
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Idiopathic myelofibrosis is a chronic myeloproliferative disorder in which the characteristic fibroblast proliferation is thought to be a secondary phenomenon resulting from the inappropriate release of megakaryocyte- and/or monocyte-derived growth factors, including PDGF, TGF-beta, bFGF and calmodulin. In contrast, the haematopoietic cells are clonal, although the underlying pathogenetic mechanisms remain essentially unknown. Cytogenetic studies have highlighted that 13q-, 20q-, +8 and abnormalities of chromosomes 1, 7 and 9 constitute more than 80% of the chromosomal changes. A third of idiopathic myelofibrosis cases have abnormal karyotypes at diagnosis, a figure that increases if follow-up analyses are performed. Evolution to more complex karyotypes may accompany clinical progression, with abnormalities increasing to around 90% following acute leukaemic transformation. Cytogenetic abnormalities have been associated with prognosis and to a lack of treatment response to androgens. Oncogene mutations are rare and include point mutations in N-RAS, c-KIT and TP53. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:113 / 119
页数:7
相关论文
共 92 条
[1]   Long-term survival of infants with idiopathic myelofibrosis [J].
Altura, RA ;
Head, DR ;
Wang, WC .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (02) :459-462
[2]   MYELOFIBROSIS WITH MYELOID METAPLASIA IN SURVIVORS OF ATOMIC BOMB IN HIROSHIMA [J].
ANDERSON, RE ;
HOSHINO, T ;
YAMAMOTO, T .
ANNALS OF INTERNAL MEDICINE, 1964, 60 (01) :1-+
[3]  
ANGER B, 1990, LEUKEMIA, V4, P258
[4]   Interstitial deletion constitutes the major mechanism for loss of heterozygosity on chromosome 20q in polycythemia vera [J].
Asimakopoulos, FA ;
Gilbert, JGR ;
Aldred, MA ;
Pearson, TC ;
Green, AR .
BLOOD, 1996, 88 (07) :2690-2698
[5]  
AWSON R, 1941, SCIENCE, V93, P541
[6]   A PROGNOSTIC CLASSIFICATION OF MYELOFIBROSIS WITH MYELOID METAPLASIA [J].
BAROSI, G ;
BERZUINI, C ;
LIBERATO, LN ;
COSTA, A ;
POLINO, G ;
ASCARI, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (04) :397-401
[7]   Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia [J].
Barosi, G ;
Viarengo, G ;
Pecci, A ;
Rosti, V ;
Piaggio, G ;
Marchetti, M ;
Frassoni, F .
BLOOD, 2001, 98 (12) :3249-3255
[8]   Molecular genetics and cytogenetics of myeloproliferative disorders [J].
Bench, AJ ;
Nacheva, EP ;
Champion, KM ;
Green, AR .
BAILLIERES CLINICAL HAEMATOLOGY, 1998, 11 (04) :819-848
[9]  
BESA EC, 1982, CANCER, V49, P308, DOI 10.1002/1097-0142(19820115)49:2<308::AID-CNCR2820490217>3.0.CO
[10]  
2-4